Krystal Biotech Inc (KRYS) - Rasio bathi reged

Lambang korporat lan logo Krystal Biotech Inc (KRYS)

Krystal Biotech, Inc. (KRYS) is scaling profits due to the low cost of goods sold for its gene gels following FDA approval. The gross margin reflects financial resilience, with the metric currently standing at 93.00. This confirms the founders' competence in commercializing therapies for orphan diseases. Current success is driven by sales of the first drug and stable insurance reimbursements.

Rentabilitas reged krystalbio.com (KRYS): kanggo periode 04.07.2022 - 20.11.2026

Rincian metrik keuangan lan pasar Krystal Biotech, Inc. (KRYS)

- kuotasi saiki lan rata-rata prakiraan nilai:
Pambiji fundamental:KRYS - Krystal Biotech Inc
Produk sing diprodhuksi Krystal Biotech Corp.

Gross margin measures production efficiency by determining the portion of revenue remaining after direct costs, which is critical for assessing the fundamental viability of a business. An analysis of the gross profit margin allows for a comparison of Krystal Biotech, Inc. (KRYS) operational profitability against the high costs of gene therapy production and licensing, revealing the company's actual ability to overcome the financial uncertainty of product commercialization.